Intravitreal antivascular endothelial growth factor drugs represent the current standard of care for neovascular age-related macular degeneration (nAMD). Individualized treatment regimens aim at obtaining the same visual benefits of monthly injections with a reduced number of injections and follow-up visits, and, consequently, of treatment burden. The target of these strategies is to timely recognize lesion recurrence, even before visual deterioration. Early detection of lesion activity is critical to ensure that clinical outcomes are not compromised by inappropriate delays in treatment, but questions remain on how to effectively monitor the choroidal neovascularization (CNV) activity. To assess the persistence/recurrence of lesion activity...
Age-related macular degeneration (AMD) is a progressive chronic disease that currently represents th...
Age-related macular degeneration (AMD) is a progressive chronic disease that currently represents th...
This Perspective discusses the pertinence of variable dosing regimens with anti-vascular endothelial...
Intravitreal antivascular endothelial growth factor drugs represent the current standard of care for...
The use of vascular endothelial growth factor (VEGF) inhibitors has revolutionised the treatment of ...
The use of vascular endothelial growth factor (VEGF) inhibitors has revolutionised the treatment of ...
The use of vascular endothelial growth factor (VEGF) inhibitors has revolutionised the treatment of ...
PURPOSE To determine the characteristics and outcomes of eyes with neovascular age-related macular d...
Purpose: To report the one and two year outcome of cycles of three, monthly anti-VEGF injections giv...
PURPOSE To determine the characteristics and outcomes of eyes with neovascular age-related macular d...
Purpose: To evaluate the association between quantitative optical coherence tomography angiography (...
Age-related macular degeneration (AMD) is a progressive chronic disease that currently represents th...
Purpose: To evaluate the association between quantitative optical coherence tomography angiography (...
Treatment of the neovascular form of age-related macular degeneration (AMD) has been revolutionized ...
AbstractAge-related macular degeneration is the leading cause of irreversible visual loss in elderly...
Age-related macular degeneration (AMD) is a progressive chronic disease that currently represents th...
Age-related macular degeneration (AMD) is a progressive chronic disease that currently represents th...
This Perspective discusses the pertinence of variable dosing regimens with anti-vascular endothelial...
Intravitreal antivascular endothelial growth factor drugs represent the current standard of care for...
The use of vascular endothelial growth factor (VEGF) inhibitors has revolutionised the treatment of ...
The use of vascular endothelial growth factor (VEGF) inhibitors has revolutionised the treatment of ...
The use of vascular endothelial growth factor (VEGF) inhibitors has revolutionised the treatment of ...
PURPOSE To determine the characteristics and outcomes of eyes with neovascular age-related macular d...
Purpose: To report the one and two year outcome of cycles of three, monthly anti-VEGF injections giv...
PURPOSE To determine the characteristics and outcomes of eyes with neovascular age-related macular d...
Purpose: To evaluate the association between quantitative optical coherence tomography angiography (...
Age-related macular degeneration (AMD) is a progressive chronic disease that currently represents th...
Purpose: To evaluate the association between quantitative optical coherence tomography angiography (...
Treatment of the neovascular form of age-related macular degeneration (AMD) has been revolutionized ...
AbstractAge-related macular degeneration is the leading cause of irreversible visual loss in elderly...
Age-related macular degeneration (AMD) is a progressive chronic disease that currently represents th...
Age-related macular degeneration (AMD) is a progressive chronic disease that currently represents th...
This Perspective discusses the pertinence of variable dosing regimens with anti-vascular endothelial...